Shares in US firm ZS Pharma (Nasdaq: ZSPH) closed up over 28% overnight Thursday on the Nasdaq, following confirmation the company is in talks with Swiss biotech firm Actelion (SIX: ATLN) for a “potential strategic transaction.”
The market value of ZS Pharma following the stock price surge stood at nearly $1.5 billion, at close Thursday.
Actelion on Thursday confirmed it is in preliminary talks with ZS Pharma, without giving out any further details in a statement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze